411 related articles for article (PubMed ID: 28387840)
1. Dose optimization of piperacillin/tazobactam in critically ill children.
De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
Cies JJ; Shankar V; Schlichting C; Kuti JL
Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
[TBL] [Abstract][Full Text] [Related]
4. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z
Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
[TBL] [Abstract][Full Text] [Related]
7. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
Jung B; Mahul M; Breilh D; Legeron R; Signe J; Jean-Pierre H; Uhlemann AC; Molinari N; Jaber S
Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
[TBL] [Abstract][Full Text] [Related]
9. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
[TBL] [Abstract][Full Text] [Related]
15. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
Felton TW; Hope WW; Lomaestro BM; Butterfield JM; Kwa AL; Drusano GL; Lodise TP
Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
18. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
19. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Kim A; Sutherland CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
